持续肾上腺素输注对危重症患者生存的影响:随机试验的荟萃分析
该荟萃分析检索截至2019年3月的PubMed、EMBASE和Cochrane数据库,纳入12项随机对照试验共1227例ICU或大手术患者,比较持续静脉输注肾上腺素与对照(最常用为去甲肾上腺素联合多巴酚丁胺)的结局。主要终点最长随访全因死亡率无显著差异(肾上腺素组197/579 [34.0%] vs 对照组219/648 [33.8%];RR=0.95;95%CI 0.82-1.10;p=0.49;I=0%)。肾脏替代治疗需求、心肌缺血发生率、心律失常发生率和ICU住院时间均无差异。结论提示当前随机证据显示持续静脉肾上腺素作为正性肌力/血管加压药不伴随更差结局。
要点
- 最长随访全因死亡率:肾上腺素组197/579(34.0%)vs 对照组219/648(33.8%),RR=0.95(95%CI 0.82-1.10;p=0.49;I=0%),无显著差异。
- 肾脏替代治疗需求、心肌缺血发生率、心律失常发生率及ICU住院时间在两组间均无差异。
- 多数试验在脓毒症休克背景下进行,最常用对照为去甲肾上腺素联合多巴酚丁胺。
- 纳入标准为持续静脉输注肾上腺素、ICU或大手术患者;排除心肺复苏等推注用法研究。
适用人群与场景
- 纳入标准:ICU住院或接受大手术的患者,且接受肾上腺素持续静脉输注。
- 排除标准:肾上腺素推注给药的研究(如心肺复苏期间)。
- 多数纳入试验在脓毒症休克背景下进行。
处置流程与药物剂量
- 干预:肾上腺素以持续静脉输注方式作为正性肌力/血管加压药使用。
- 最常用对照:去甲肾上腺素联合多巴酚丁胺。
研究设计与关键结果
- 研究类型:随机对照试验的系统综述与荟萃分析,共纳入12项研究、1227例患者。
- 检索来源:PubMed、EMBASE和Cochrane central register,检索截至2019年3月。
- 主要终点最长随访全因死亡率:肾上腺素组197/579(34.0%)vs 对照组219/648(33.8%);RR=0.95;95%CI 0.82-1.10;p=0.49;I=0%。
- 肾脏替代治疗需求、心肌缺血发生率、心律失常发生率及ICU住院时间均无差异。
证据类型、等级与局限
- 证据类型:随机对照试验的系统综述与荟萃分析。
- 异质性:I=0%。
- 局限:原文未报告局限性。
对床旁实践的改变
- 当前随机证据显示,持续静脉输注肾上腺素作为正性肌力/血管加压药不伴随危重症患者更差的结局。
- 多数试验在脓毒症休克背景下进行,最常用对照为去甲肾上腺素联合多巴酚丁胺。
- 该分析排除肾上腺素推注给药(如心肺复苏期间)的研究,结论不适用于推注用法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Epinephrine is frequently used as an inotropic and vasopressor agent in critically ill patients requiring hemodynamic support. Data from observational trials suggested that epinephrine use is associated with a worse outcome as compared with other adrenergic and nonadrenergic vasoactive drugs. We performed a systematic review and meta-analysis of randomized controlled trials to investigate the effect of epinephrine administration on outcome of critically ill patients.
DATA SOURCES: PubMed, EMBASE, and Cochrane central register were searched by two independent investigators up to March 2019.
STUDY SELECTION: Inclusion criteria were: administration of epinephrine as IV continuous infusion, patients admitted to an ICU or undergoing major surgery, and randomized controlled trials. Studies on epinephrine administration as bolus (e.g., during cardiopulmonary resuscitation), were excluded. The primary outcome was mortality at the longest follow-up available.
DATA EXTRACTION: Two independent investigators examined and extracted data from eligible trials.
DATA SYNTHESIS: A total of 5,249 studies were assessed, with a total of 12 studies (1,227 patients) finally included in the meta-analysis. The majority of the trials were performed in the setting of septic shock, and the most frequent comparator was a combination of norepinephrine plus dobutamine. We found no difference in all-cause mortality at the longest follow-up available (197/579 [34.0%] in the epinephrine group vs 219/648 [33.8%] in the control group; risk ratio = 0.95; 95% CI, 0.82-1.10; p = 0.49; I = 0%). No differences in the need for renal replacement therapy, occurrence rate of myocardial ischemia, occurrence rate of arrhythmias, and length of ICU stay were observed.
CONCLUSIONS: Current randomized evidence showed that continuous IV administration of epinephrine as inotropic/vasopressor agent is not associated with a worse outcome in critically ill patients.
参考来源
- Belletti A, Nagy A, Sartorelli M, et al. Effect of Continuous Epinephrine Infusion on Survival in Critically Ill Patients: A Meta-Analysis of Randomized Trials. Crit Care Med. 2020. PMID: 31789701. doi:10.1097/CCM.0000000000004127
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。